← back to search

Orhan Aktaş

Düsseldorf University Hospital · DE
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Systemic Lupus Erythematosus Research, and Ocular Diseases and Behçet’s Syndrome.
h-index
78
citations
25,349
works
419
NIH funding
primary concept
email

Recent publications

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin‐4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease: Exploratory Study From the <scp>CROCTINO</scp> Cohort
European Journal of Neurology 2025cited by 9position: middledoi
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis
EBioMedicine 2025cited by 5position: middledoi
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)
Frontiers in Immunology 2025cited by 4position: middledoi
Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study)
BMJ Neurology Open 2025cited by 2position: middledoi
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
The Lancet Neurology 2024cited by 49position: middledoi
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories
Science Translational Medicine 2024cited by 38position: middledoi
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis
Journal of Neurology 2024cited by 32position: middledoi
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation
Brain 2024cited by 29position: middledoi
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD
Journal of Neurology Neurosurgery & Psychiatry 2024cited by 21position: middledoi
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)
Journal of Neurology Neurosurgery & Psychiatry 2024cited by 16position: middledoi
Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
Nature Communications 2024cited by 15position: middledoi
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
Neurology and Therapy 2024cited by 14position: middledoi
Rapid differentiation of MOGAD and MS after a single optic neuritis
Journal of Neurology 2024cited by 10position: middledoi
Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
Journal of Neurology 2024cited by 9position: middledoi
Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity—a potential diagnostic pitfall in patients with MOG-EM/MOGAD
Journal of Neurology 2024cited by 7position: middledoi
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
Journal of Neurology 2023cited by 219position: middledoi
Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
Journal of Neurology 2023cited by 203position: middledoi
Time to Disability Milestones and Annualized Relapse Rates in <scp>NMOSD</scp> and <scp>MOGAD</scp>
Annals of Neurology 2023cited by 63position: middledoi
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
Journal of Neurology Neurosurgery & Psychiatry 2023cited by 42position: firstdoi
Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination
JAMA Neurology 2023cited by 32position: middledoi
Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
Scientific Reports 2023cited by 26position: middledoi
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
Multiple Sclerosis Journal 2023cited by 22position: middledoi
Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
Journal of Neurology Neurosurgery & Psychiatry 2023cited by 18position: middledoi
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of <scp><i>FCGR3A</i></scp> polymorphism
Annals of Clinical and Translational Neurology 2023cited by 18position: middledoi
Retinal Changes After Acute and Late Optic Neuritis in Aquaporin-4 Antibody Seropositive NMOSD
Journal of Neuro-Ophthalmology 2023cited by 5position: middledoi
Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017)
Neurology 2023cited by 1position: middledoi
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients
Journal of Neuroinflammation 2022cited by 161position: middledoi
Thinking outside the box: non-canonical targets in multiple sclerosis
Nature Reviews Drug Discovery 2022cited by 112position: middledoi
Longitudinal Retinal Changes in <scp>MOGAD</scp>
Annals of Neurology 2022cited by 56position: middledoi
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
EBioMedicine 2022cited by 39position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Friedemann Paul · Max Delbrück Center29 papers (2013–2024)Hans‐Peter Hartung · The University of Sydney18 papers (2014–2024)Sven Jarius · Heidelberg University12 papers (2013–2024)Ho Jin Kim · National Cancer Center12 papers (2015–2024)Jeffrey L. Bennett · University of Colorado Denver11 papers (2015–2024)Bruce Cree · California State University, Bakersfield11 papers (2015–2024)Marius Ringelstein · Antea Group (France)11 papers (2013–2024)Brian G. Weinshenker · Mayo Clinic11 papers (2015–2024)Kazuo Fujihara · Fukushima Medical University10 papers (2015–2024)Romain Marignier · Hospices Civils de Lyon10 papers (2013–2024)Dewei She · Amgen (United States)10 papers (2019–2024)Eliezer Katz · Psyadon Pharmaceuticals (United States)10 papers (2015–2024)Philipp Albrecht · Universitäts-Herzzentrum Freiburg-Bad Krozingen10 papers (2014–2023)Klemens Ruprecht · Heidelberg University10 papers (2018–2024)Dean M. Wingerchuk · University of Colorado Denver9 papers (2015–2024)Brigitte Wildemann · Heidelberg University9 papers (2013–2024)Gary Cutter · Epilepsy Foundation9 papers (2015–2024)Daniel Cimbora · Amgen (United States)8 papers (2019–2024)Ingo Kleiter · Dentsply Sirona (United States)8 papers (2013–2023)Ari Green · University of California, San Francisco8 papers (2019–2024)